美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

NETLease Corporate Real Estate ETF

24.66

-0.1671-0.67%

盤後：24.660.00000.00%19:30 EDT

成交量：3.99萬

成交額：98.49萬

市值：4,870.35萬

市盈率：- -

高：24.75

開：24.72

低：24.63

收：24.83

52周最高：28.43

52周最低：23.56

股本：197.50萬

流通股本：197.50萬

量比：1.71

換手率：2.02%

股息：1.25

股息率：5.08%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

百利天恒：雙抗ADC藥物非小細胞肺癌III期臨床達主要終點

博安生物(06955)：BA1302 (CD228 ADC)完成中國Ia期臨床研究

艾力斯醫藥獲得ArriVent潛在全球首創ADC權益；京東健康上半年累計首發65款新藥 | 醫藥早參

每日经济新闻

第一三共/阿斯利康(AZN.US)重磅ADC藥物「德曲妥珠單抗」又一項新適應症在中國獲批上市

優赫得聯合帕妥珠單抗在華獲批HER2陽性轉移性乳腺癌一線治療，成為十餘年來該領域首個獲批的創新ADC方案

Realty Income宣佈發行7.5億美元可轉換債券後股價下跌

Realty Income Corporation 計劃動用部分淨收益同步回購普通股

加拿大H&R 房地產投資信託基金將被收購，對價為每單位 12.01 加元。

ADC的礦源耗竭了嗎？

百濟神州：公司擬披露CEA ADC在非小細胞肺癌中的早期數據，覆蓋鱗癌和非鱗癌患者

再鼎醫藥2026 Q2產品按月收入增長11%，DLL3 ADC最快明年提交美國上市申請

印度市場監管機構提議允許基礎設施投資信託和房地產投資信託在不持有控股權的前提下投資在建項目。

港股異動 | 科倫博泰生物(06990)午前升逾4% 新型雙載荷ADC藥物SKB565新藥臨床試驗申請獲批

Realty Income 因租金上漲而上調了 2026 年的運營資金預測

Realty Income第二季度運營資金（FFO）每股1.07美元，收益表現穩健

Realty Income公司上調2026年每股AFFO指引，中點增速約達4%

22億美元ADC出海改寫康寧傑瑞

国际金融报

港股異動 | 百奧賽圖-B(02315)升逾10% 雙抗ADC推進海外開發臨床前CRO與模型鼠景氣度上行

康寧傑瑞製藥-B早盤升逾12% TROP2/HER3雙抗ADC授權出海

中國生物製藥(01177)：TQB2102「HER2雙抗ADC」第三次被CDE納入突破性治療藥物名單

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/NETL/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"NETL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","market":"US","secType":"STK","nameCN":"NETLease Corporate Real Estate ETF","latestPrice":24.66,"timestamp":1789761600000,"preClose":24.8271,"halted":0,"volume":39852,"hourTrading":{"tag":"盘后","latestPrice":24.66,"preClose":24.66,"latestTime":"19:30 EDT","volume":12,"amount":295.92,"timestamp":1789774204758,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.006730548473240988,"floatShares":1975000,"shares":1975000,"eps":0,"marketStatus":"休市中","change":-0.1671,"latestTime":"09-18 16:00:00 EDT","open":24.72,"high":24.75,"low":24.625,"amount":984852.7122600001,"amplitude":0.005035,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":24.8271,"sharesOutstanding":1775000,"nav":24.81,"aum":48999750,"dividendRate":0.050843,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":24.66,"preClose":24.66,"latestTime":"19:30 EDT","volume":12,"amount":295.92,"timestamp":1789774204758,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.7068553603405197,"impliedVol":0.0619,"impliedVolPercentile":0.0637},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NETL\",,,,,undefined,":{"symbol":"NETL","floatShares":1975000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.7068553603405197,"shares":1975000,"dividePrice":1.2538,"high":24.75,"amplitude":0.005035,"preClose":24.8271,"low":24.625,"week52Low":23.56,"pbRate":"--","week52High":28.4299,"institutionHeld":0,"latestPrice":24.66,"eps":0,"divideRate":0.050843,"volume":39852,"delay":0,"ttmEps":0,"open":24.72,"prevYearClose":23.727,"prevWeekClose":25.5596,"prevMonthClose":26.1278,"prevQuarterClose":26.7001,"fiveDayClose":25.5596,"twentyDayClose":26.7647,"sixtyDayClose":26.6442},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NETL\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-08-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-27","defaultRemindTime":1787837400000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-27","currency":"USD","dateTimestamp":1787803200000,"payDate":"2026-08-31"},{"date":"2026-07-29","symbol":"NETL","amount":0.105,"announcedDate":"2026-07-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-29","defaultRemindTime":1785331800000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-31","payableDate":"2026-07-29","currency":"USD","dateTimestamp":1785297600000,"payDate":"2026-07-31"},{"date":"2026-06-26","symbol":"NETL","amount":0.105,"announcedDate":"2026-06-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-26","defaultRemindTime":1782480600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-30","payableDate":"2026-06-26","currency":"USD","dateTimestamp":1782446400000,"payDate":"2026-06-30"},{"date":"2026-05-27","symbol":"NETL","amount":0.105,"announcedDate":"2026-05-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-27","defaultRemindTime":1779888600000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-29","payableDate":"2026-05-27","currency":"USD","dateTimestamp":1779854400000,"payDate":"2026-05-29"},{"date":"2026-04-28","symbol":"NETL","amount":0.105,"announcedDate":"2026-04-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-04-28","defaultRemindTime":1777383000000,"name":"NETLease Corporate Real Estate ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-30","payableDate":"2026-04-28","currency":"USD","dateTimestamp":1777348800000,"payDate":"2026-04-30"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NETL\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-30","recordDate":"2019-12-31","paymentDate":"2020-01-02","value":0.031935,"currency":"USD"},{"executeDate":"2020-03-17","recordDate":"2020-03-18","paymentDate":"2020-03-19","value":0.0097783,"currency":"USD"},{"executeDate":"2020-03-31","recordDate":"2020-04-01","paymentDate":"2020-04-02","value":0.1912399,"currency":"USD"},{"executeDate":"2020-06-26","recordDate":"2020-06-29","paymentDate":"2020-06-30","value":0.2782635,"currency":"USD"},{"executeDate":"2020-09-15","recordDate":"2020-09-16","paymentDate":"2020-09-30","value":0.2792338,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NETL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NETL\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660486161","title":"百利天恒：雙抗ADC藥物非小細胞肺癌III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2660486161","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660486161?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 17:34","pubTimestamp":1786959283,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4134","NETL","ADC","BK4231","BK4080","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147909","title":"博安生物(06955)：BA1302 (CD228 ADC)完成中國Ia期臨床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659147909?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 22:22","pubTimestamp":1786717377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，公司自主研发的靶向CD228的创新抗体偶联药物BA1302已完成中国I期临床研究单药剂量递增阶段(Ia期)。研究结果显示，BA1302在经多线治疗后疾病仍进展的多种晚期实体瘤患者中展现出良好的抗肿瘤活性，整体安全耐受性良好。据公司所知，BA1302是目前全球唯一处于临床阶段的靶向CD228 ADC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06955","BK4080","BK4231","BK1161","NETL","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659618195","title":"艾力斯醫藥獲得ArriVent潛在全球首創ADC權益；京東健康上半年累計首發65款新藥 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2659618195","media":"每日经济新闻","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659618195?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 07:01","pubTimestamp":1786662085,"startTime":"0","endTime":"0","summary":"丨2026年8月14日星期五丨NO.1艾力斯医药获得ArriVent潜在全球首创ADC权益8月13日，艾力斯宣布与ArriVentBioPharma,Inc.(ArriVent)签署战略合作协议，公司获得在中国研究、开发、生产、注册以及商业化抗体偶联药物（ADC）AST12608/ARR-002的独占许可。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608143840884969.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608143840884969.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","BK1247","06618","LU0456827905.SGD","SGXZ62798434.SGD","BK1574","BK4231","86618","NETL","SGXZ86797644.SGD","BK1589","159938","BK1515","BK1142","BK1161","688578","09939","ADC","BK1571","BK0239","BK1591","BK1615","BK1583","LU0051755006.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659860121","title":"第一三共/阿斯利康(AZN.US)重磅ADC藥物「德曲妥珠單抗」又一項新適應症在中國獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2659860121","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659860121?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 07:21","pubTimestamp":1786576889,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月12日，第一三共宣布，其与阿斯利康合作开发的重磅ADC药物“德曲妥珠单抗”一项新适应症获批上市，适应症为联合帕妥珠单抗用于不可切除或转移性HER2阳性成人乳腺癌患者的一线治疗。德曲妥珠单抗(DS-8201，商品名：优赫得®/Enhertu)是一款靶向HER2的ADC药物，由第一三共开发，并与阿斯利康在全球范围内共同开发和商业化。该药由HER2靶向抗体、可裂解四肽连接子和拓扑异构酶I抑制剂DXd(依喜替康衍生物)组成，DAR约为8。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","LU2237443465.HKD","NETL","BK4568","LU0058720904.USD","LU2237443549.SGD","LU2236285917.USD","BK4007","LU2089984988.USD","LU2237443382.USD","LU0289739699.SGD","LU2462157665.USD","AZNH","LU0889565916.HKD","LU2237443895.HKD","BK4080","LU0320765992.SGD","LU0109394709.USD","LU0708994859.HKD","LU1829250122.USD","LU2468319806.SGD","LU2417539215.USD","IPOS","ADC","AZN","BK4585","IE00B3T34201.USD","LU0432979614.USD","LU2237443978.SGD","LU0128525929.USD","BK4231","LU0310800379.SGD","LU0029864427.USD","LU2456880835.USD","LU2237443622.USD","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658976102","title":"優赫得聯合帕妥珠單抗在華獲批HER2陽性轉移性乳腺癌一線治療，成為十餘年來該領域首個獲批的創新ADC方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2658976102","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658976102?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 17:15","pubTimestamp":1786526100,"startTime":"0","endTime":"0","summary":"德曲妥珠单抗联合帕妥珠单抗组的PFS获益在各个预设亚组中均保持一致。在DESTINY-Breast09研究中，德曲妥珠单抗联合帕妥珠单抗治疗的中位无进展生存期超过三年，有望成为这一领域新的标准治疗，期待此治疗方案能使更多中国患者受益。此次获批标志着这一创新治疗方案进入了HER2阳性转移性乳腺癌更前线治疗阶段。此次获批标志着德曲妥珠单抗在中国迎来第八项适应症，其中五项为乳腺癌治疗领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5024779_ZH24779_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5024779_ZH24779_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0310800379.SGD","LU2237443382.USD","LU2237443622.USD","LU0058720904.USD","LU2237443549.SGD","LU2462157665.USD","BK4231","LU0128525929.USD","BK4585","LU0889565916.HKD","LU2237443895.HKD","NETL","LU1829250122.USD","AZNH","LU0029864427.USD","ADC","BK4080","LU0289739699.SGD","LU2417539215.USD","IE00B3T34201.USD","LU2089984988.USD","LU1267930573.SGD","LU2468319806.SGD","LU2237443465.HKD","LU0320765992.SGD","LU0708994859.HKD","LU0109394709.USD","LU2237443978.SGD","AZN","BK4588","LU0432979614.USD","LU2456880835.USD","LU2236285917.USD","BK4007","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658620945","title":"Realty Income宣佈發行7.5億美元可轉換債券後股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2658620945","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658620945?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 04:45","pubTimestamp":1786481154,"startTime":"0","endTime":"0","summary":"年初至今，该股上涨9.8%，与标普500房地产板块约10%的涨幅基本持平.SPLRCR** 据LSEG数据显示，26位分析师的平均评级为“持有”；目标价中位数为68美元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL4S4481GX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFAR","SRHR","TSRS","BK4080","RWR","CLIM","BK4231","DPRE","BK4588","ERET","O","NETL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152707573","title":"Realty Income Corporation 計劃動用部分淨收益同步回購普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1152707573","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152707573?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 04:07","pubTimestamp":1786478820,"startTime":"0","endTime":"0","summary":"Realty Income Corporation 宣布，其计划利用部分净收益，同步开展普通股的回购操作。这一举措，预计将借助募集资金，在市场上对自身股票进行买回。此举旨在优化资本结构，并传递出对自身价值的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSRS","DFAR","RWR","NETL","BK4080","BK4588","O","BK4585","SRHR","CLIM","ERET","BK4231","DPRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658999246","title":"加拿大H&R 房地產投資信託基金將被收購，對價為每單位 12.01 加元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658999246","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658999246?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 18:04","pubTimestamp":1786442652,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","JPRE","BK4550","XSHD","BLDG","BK4007","IYLD","VRAI","CRIB","REAI","KBWD","SPHD","ABLD","IVRA","AVRE","DFRA","FPRO","NETL","GRI","INDS","FREI","RNTY","DTRE","GARA","IQRA","RWO","IDGT","CSRE","SPRE","MDIV","HIPS","ALTY","ASET","VGSR","DPRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657622723","title":"ADC的礦源耗竭了嗎？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657622723","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657622723?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 11:39","pubTimestamp":1786160396,"startTime":"0","endTime":"0","summary":"于是我们听见，行业里开始流行一句半开玩笑的问话：ADC的矿源耗竭了吗？01 三代挖矿者同挖一座山ADC的矿，指的是可成药抗原：抗体识别细胞表面靶点，偶联毒素定向爆破。但到2026年，矿脉分布已经畸形：HER2：全球临床试验318项，中国企业在该靶点ADC在研数量占全球63.6%，2026年ASCO摘要池里HER2相关48个分子、104项研究，Enhertu一家占了21条。02 开采成本翻了几倍矿源耗竭的体感，来自五重挤压。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1785379137813045498","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4231","ADC","NETL","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641539","title":"百濟神州：公司擬披露CEA ADC在非小細胞肺癌中的早期數據，覆蓋鱗癌和非鱗癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641539","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641539?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 21:24","pubTimestamp":1786109040,"startTime":"0","endTime":"0","summary":"百济神州在接受调研时表示，公司拟披露CEA ADC在非小细胞肺癌中的早期数据，覆盖鳞癌和非鳞癌患者。具体的CEA表达阈值、PD-L1表达分层及对应疗效尚未对外披露，后续数据将提供更多信息。公司不会将该产品局限于后线，正在加快向更前线及与PD-1等方案联合推进。对于CEA与KRAS共突变等细分人群，也会根据表达重叠度和早期信号开展探索。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyi4628080.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyi4628080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","LU1719994722.HKD","ONC","BK4585","688235","LU1969619763.USD","NETL","BK4588","BK1500","BK1161","BK4080","LU0588546209.SGD","06160","LU2328871848.SGD","BK4139","LU1303224171.USD","BK4231","ADC","BK1588","BK4526","LU0307460666.USD","BK0239","KURE","LU1251922891.USD","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657259635","title":"再鼎醫藥2026 Q2產品按月收入增長11%，DLL3 ADC最快明年提交美國上市申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2657259635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657259635?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 19:46","pubTimestamp":1786016812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NETL","BK4585","BK4531","BK4526","IPOS","LU2488822045.USD","BK4588","BK4080","ZLAB","BK4548","BK4231","BK4139","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657870086","title":"印度市場監管機構提議允許基礎設施投資信託和房地產投資信託在不持有控股權的前提下投資在建項目。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657870086","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657870086?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 18:46","pubTimestamp":1786013180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["KBWD","HIPS","RWO","IUSA","INDL","INQQ","RJZ","NETL","FREI","AMER","RSPN","SPHD","ARCAY","SMIN","IYLD","HALX","AVRE","REAI","DPRE","INDY","GRI","CSRE","PPI","ERH","INCO","XLIX","NDIA","ALTY","FLIBF","IQRA","XSHD","JPRE","BCIM","MDIV","VOE","INDE","SLX","ABLD","DTRE","DFRA","FIDU","IVRA","INDS","RNTY","VGSR","SPRE","BLDG","IDGT","IND","GLIN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657505243","title":"港股異動 | 科倫博泰生物(06990)午前升逾4% 新型雙載荷ADC藥物SKB565新藥臨床試驗申請獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2657505243","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657505243?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 11:16","pubTimestamp":1785986197,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物(06990)午前涨超4%，截至发稿，涨3.8%，报510.5港元，成交额9592.4万港元。消息面上，科伦博泰生物近日发布公告，公司收到国家药品监督管理局药品审评中心的临床试验通知书，同意其新型双载荷ADC药物SKB565的新药临床试验申请，用于治疗晚期实体瘤。这是公司首个进入临床阶段的“双载荷”抗体偶联药物，SKB565的获批标志着公司在“ADC+IO”一体化开发策略上迈出关键一步。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","PSYK","NETL","BK4588","MDTX","IBBJ","06990","ADC","BMED","BK4585","KCAI","LU0196878994.USD","IBBQ","BK4231","BK4080","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657539575","title":"Realty Income 因租金上漲而上調了 2026 年的運營資金預測","url":"https://stock-news.laohu8.com/highlight/detail?id=2657539575","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657539575?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 04:44","pubTimestamp":1785962687,"startTime":"0","endTime":"0","summary":"Realty Income 因租金上涨而上调了 2026 年的运营资金预测8月5日-Realty Income（O.N）周三上调了年度经调整运营资金的预测，凭借物业租金的更高增长。详情如下：该公司的客户包括沃尔格林和美元通用等，预计2026年经调整的运营资金将在每股4.44美元至4.45美元之间，而此前预测为4.41美元至4.44美元。随着人工智能热潮推动计算能力需求上升，Realty一直在扩大对数据中心物业的投资。Realty将全年投资预测从之前的95亿美元上调至100亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL4T4422H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4114","BK4231","LU1861215975.USD","DPRE","DFAR","LU0724618433.USD","BK4080","LU2298322129.HKD","IE00BFMHRM44.USD","LU1854104046.USD","BK4585","IE00BD6J9T35.USD","IE00BZ199S13.USD","LU1720051017.SGD","BK4504","BK4512","BK4588","LU1720051108.HKD","LU0124384867.USD","LU0072461881.USD","BK4605","LU0070302665.USD","LU2360107325.USD","LU0320765489.SGD","DG","LU1989763427.SGD","LU2357305700.SGD","LU0208291251.USD","NETL","CLIM","ON","LU1861219969.SGD","LU1978683503.SGD","LU1585245621.USD","RWR","LU1854103824.USD","LU0162691827.USD","LU1989763690.USD","BK4155","BK4141","TSRS","ERET","LU1861214812.USD","LU1548497426.USD","LU0348723411.USD","SRHR","LU1430594728.SGD","LU1983260115.SGD","LU1861220033.SGD","O"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146241333","title":"Realty Income第二季度運營資金（FFO）每股1.07美元，收益表現穩健","url":"https://stock-news.laohu8.com/highlight/detail?id=1146241333","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146241333?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 04:28","pubTimestamp":1785961712,"startTime":"0","endTime":"0","summary":"根据8月5日发布的最新财报，房地产投资信托公司Realty Income Corp在第二季度交出了一份引人注目的成绩单。其运营资金达到每股1.07美元，这一数据反映出公司核心业务的内在活力。与此同时，该公司的每股收益为0.37美元。这些数字并不仅仅是简单的财务指标，它们背后隐藏着Realty Income在多变市场环境中的韧性与策略。在宏观经济波动与利率环境变化的背景下，Realty Income的这一成绩显得尤为亮眼。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RWR","SRHR","BK4585","ERET","DPRE","BK4231","DFAR","TSRS","BK4080","NETL","BK4588","CLIM","O"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153061120","title":"Realty Income公司上調2026年每股AFFO指引，中點增速約達4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153061120","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153061120?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 04:20","pubTimestamp":1785961203,"startTime":"0","endTime":"0","summary":"Realty Income Corporation发布最新动态：其2026年调整后运营资金（AFFO）每股指引已获上调。分析指出，这一调整后的指引中点，所反映的增长率大约为4%。这表明，公司对未来盈利能力的预期正趋于乐观。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ERET","NETL","SRHR","O","BK4585","RWR","BK4080","DFAR","TSRS","DPRE","BK4231","CLIM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657516276","title":"22億美元ADC出海改寫康寧傑瑞","url":"https://stock-news.laohu8.com/highlight/detail?id=2657516276","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657516276?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 15:09","pubTimestamp":1785913740,"startTime":"0","endTime":"0","summary":"站在行业发展的角度看，双抗ADC，正在成为国产创新药出海的全新增长极。8月4日，康宁杰瑞生物制药发布重磅公告，旗下全球首创TROP2/HER3双特异性抗体偶联药物（ADC）JSKN016达成海外独家授权合作，与美国AI驱动肿瘤新药研发企业PathosAI签约，交易总潜在金额最高达22.18亿美元（约合142.2亿元），创下国产双抗ADC出海的新里程碑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608053832538126.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608053832538126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BFMHRM44.USD","LU2265009873.SGD","GLWG","BK4148","BK4585","ADC","CNAV","BK4512","LU1720051108.HKD","LU2322448957.HKD","LU2543165471.USD","LU2272731782.SGD","LU1720051017.SGD","LU1548497426.USD","LU2272731600.USD","LU0348723411.USD","BK4231","LU2322448791.USD","LU1992135399.USD","LU2357305700.SGD","RULE","BK4588","GLW","LU2473716301.USD","BK4080","LU1804176565.USD","NETL","LU1992135472.HKD","LU2272731865.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656538672","title":"港股異動 | 百奧賽圖-B(02315)升逾10% 雙抗ADC推進海外開發 臨床前CRO與模型鼠景氣度上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2656538672","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656538672?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 15:00","pubTimestamp":1785826839,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超10%，截至发稿，涨10.39%，报57.9港元，成交额8028.46万港元。消息面上，百奥赛图上月宣布与Whitehawk Therapeutics, Inc.签署一项全球战略合作协议，涵盖多个双特异性抗体偶联药物研发项目，双方将共同推进多元化的新一代治疗产品管线。据悉，从双方正式启动合作到完成协议签署，历时仅仅约四个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","688796","KCAI","02315","ADC","BK4080","BK4231","BK0216","NETL","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656963586","title":"康寧傑瑞製藥-B早盤升逾12% TROP2/HER3雙抗ADC授權出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2656963586","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656963586?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 09:54","pubTimestamp":1785808440,"startTime":"0","endTime":"0","summary":"模拟交易客户端康宁杰瑞制药-B早盘涨超12%，截至发稿，股价上涨12.43%，现报8.32港元，成交额762.18万港元。康宁杰瑞生物制药宣布，其全资子公司江苏康宁杰瑞生物制药有限公司与Pathos AI， Inc．就康宁杰瑞自主研发的同类首创新药TROP2/HER3双特异性抗体偶联药物JSKN016达成授权许可协议。作为本次授权合作的一部分，康宁杰瑞获得Pathos授予的一份认股权证，有权认购Pathos的优先股股份，认购总价为6，250万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-04/doc-inimchzt5433129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4080","BK4231","09966","BK1574","BK1161","NETL","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656248463","title":"中國生物製藥(01177)：TQB2102「HER2雙抗ADC」第三次被CDE納入突破性治療藥物名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2656248463","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656248463?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 16:37","pubTimestamp":1785746238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB2102“HER2双抗 ADC”已被中国国家药品监督管理局药品审评中心纳入突破性治疗药物名单，用于在复发或转移性疾病阶段未接受过化疗的不可切除或转移性HER2低表达成人乳腺癌患者。这是继HER2阳性早期乳腺癌新辅助治疗、HER2 IHC 3+晚期结直肠癌之后，TQB2102获得的第三项突破性疗法认定，进一步印证了其在HER2表达实体瘤治疗领域的广泛应用潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223083913.SGD","BK1589","BK4017","ADC","BK1515","NETL","XME","BK1191","LU1223082196.USD","BK4231","BK1521","BK4080","LU1223082519.USD","HK0000165453.HKD","IE00BZ08YS42.EUR","GDXJ","IE00BZ08YT58.USD","SGDM","01177","IE00BZ08YR35.GBP","SIL","CDE"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":64,"code":"91000000","status":"200"}]}}